J9022
J9022 – Injection, atezolizumab, 10 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 2 NDCs crosswalked per 10 MG $96.546/unit ASP+6%
📋 J9022 summary
J9022 is a HCPCS Level II J-code used to bill atezolizumab, 10 mg, billed per 10 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9022: Tecentriq
Code J9022
Billing unit 10 MG Payment limit $96.546/unit NDC-Crosswalk 2
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9022
DescriptorInjection, atezolizumab, 10 mg
Billing unit10 MG
Payment limit / unit$96.546
Est. ASP / unit$91.081 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20
💊 About Atezolizumab Injection DRUG GUIDE
Tecentriq (atezolizumab) is used to treat a range of cancers in adults.
It can be used alone or combined with other cancer medicines depending on the cancer type and stage.
Approved uses include non-small cell lung cancer (NSCLC) — both after surgery and in metastatic (spread) disease — extensive-stage small cell lung cancer (ES-SCLC), unresectable or metastatic hepatocellular carcinoma (liver cancer), BRAF V600 mutation-positive melanoma, and muscle invasive bladder cancer after surgery.Tecentriq is also approved — as a single agent — for adult and pediatric patients aged 2 and older with unresectable or metastatic alveolar soft part sarcoma (ASPS), a rare soft tissue cancer.
Several of these uses require tumor testing (such as PD-L1 expression or specific gene mutations) before Tecentriq is selected as treatment.
Clinical overview from our editorial drug guide for Atezolizumab Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$96.546
Est. ASP / unit
$91.081 est.
Est. after 2% sequester
$94.615
HCPCS dosage
10 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, atezolizumab, 10 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2018-01-01
Date added2018-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9022 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9022 WITH EST. MEDICARE PAY
2 NDCs map to J9022. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($96.546/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 50242-0917-01 | TECENTRIQ atezolizumab 1200 mg/20mL INJECTION, SOLUTION | Genentech, | 1 VIAL, SINGLE-USE in 1 CARTON (50242-917-... | 1200 mg/20mL | 120 | $11,585.52 | — | ● Active | CMS ASP |
| 50242-0918-01 | TECENTRIQ atezolizumab 840 mg/14mL INJECTION, SOLUTION | Genentech, | 1 VIAL, SINGLE-USE in 1 CARTON (50242-918-... | 840 mg/14mL | 84 | $8,109.86 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$153.47M
Claims
13,217
Beneficiaries
4,846
Spend / beneficiary
$31,670.38
Spend / claim
$11,611.91
Trend by period
Where J9022 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #20 of 824
#15
ENHERTU J9358
$209.39M
#16
GAMMAGARD LIQUID J1569
$182.71M
#17
ENTYVIO J3380
$180.78M
#18
ULTOMIRIS J1303
$178.93M
#19
GAMMAKED* J1561
$164.01M
#20
TECENTRIQ J9022
$153.47M
#21
OCREVUS J2350
$143.97M
#22
YERVOY J9228
$137.56M
#23
LEQVIO J1306
$137.07M
#24
BOTOX COSMETIC* J0585
$126.15M
#25
PRIVIGEN J1459
$124.34M
Total claims — #144 of 824
#139
ACTIVASE* J2997
13,490
#140
LUCENTIS J2778
13,447
#141
INFED J1750
13,385
#142
GENTAMICIN SULFATE I... J1580
13,327
#143
ALIMTA* J9305
13,253
#144
TECENTRIQ J9022
13,217
#145
HIZENTRA J1559
13,119
#146
IPRATROPIUM BROMIDE J7644
12,953
#147
ERTAPENEM J1335
12,875
#148
ENGERIX-B ADULT(9074... 90746
12,582
#149
PYRIDOXINE HCL J3415
12,475
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $153.47M | 4,846 | 13,217 | $31,670.38 | $11,611.91 |
| 2025 (Q1-Q4) | $613.14M | 8,792 | 54,073 | $69,738.90 | $11,339.20 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$211.03M
Medicare paid
$163.28M
Submitted services
2,456,025
Denial rate
3.5%
Allowed / service
$89.06
Submitted charges
$537.41M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J9022 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 92,688 services across 8 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9022 billing FAQ
What is HCPCS code J9022?
J9022 is a HCPCS Level II J-code used to bill Injection, atezolizumab, 10 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9022?
One unit of J9022 represents 10 MG. Report the number of units equal to the dose administered divided by 10 MG.
How many units of J9022 should I bill?
Divide the dose administered by the code's unit size (10 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9022?
The Medicare Part B payment limit is $96.546 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $94.615 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9022?
2 NDCs currently map to J9022 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9022 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.